Genome & Company (KOSDAQ:314130)

South Korea flag South Korea · Delayed Price · Currency is KRW
6,400.00
-350.00 (-5.19%)
At close: Feb 26, 2026
123.78%
Market Cap 221.92B
Revenue (ttm) 25.95B
Net Income (ttm) -27.82B
Shares Out 34.89M
EPS (ttm) -693.34
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 704,303
Average Volume 592,966
Open 6,750.00
Previous Close 6,750.00
Day's Range 6,400.00 - 6,750.00
52-Week Range 2,170.00 - 10,180.00
Beta 1.06
RSI 37.22
Earnings Date Nov 14, 2025

About Genome & Company

Genome & Company, a clinical stage biotechnology company, researches and develops novel-targeted immuno-oncology therapeutics in the field of immuno-oncology, skin diseases, and autism in South Korea, Asia, Europe, South America, North America, and internationally. Its lead product candidate is GEN-001, an oral microbiome therapeutic candidate developed to have immune modulating activities. The company also develops GEN-501 targeting the non-responders of Dupilumab drugs with atopic skin diseases; and GENA-104 for the treatment of solid tumors,... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2015
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 314130
Full Company Profile

Financial Performance

In 2024, Genome & Company's revenue was 27.74 billion, an increase of 94.07% compared to the previous year's 14.30 billion. Losses were -20.11 billion, -57.63% less than in 2023.

Financial Statements

News

There is no news available yet.